Hypertension Associated With Bevacizumab
- 1 August 2005
- journal article
- review article
- Published by Oncology Nursing Society (ONS) in Clinical Journal of Oncology Nursing
- Vol. 9 (4) , 407-411
- https://doi.org/10.1188/05.cjon.407-411
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Antivascular Endothelial Growth Factor Monoclonal Antibody Therapy: A Promising Paradigm in Colorectal CancerClinical Journal of Oncology Nursing, 2005
- Therapeutic Options in the Management of Colon Cancer: 2005 UpdateClinical Journal of Oncology Nursing, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Targeted Therapy of Colorectal Cancer: Clinical Experience with BevacizumabThe Oncologist, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003